Zimmer Biomet (ZBH) received the CE Mark for its Persona Revision Knee System. This addition to the Persona family builds on Zimmer Biomet’s commitment to personalized solutions, providing surgeons with advanced tools for revision knee arthroplasty. “After the successful introduction of Persona Revision Knee in the United States and other markets, the CE Mark certification and commercial launch extends its availability significantly so that more surgeons have access to an innovative solution that can enhance patient outcomes,” said Joe Urban, President, Knees at Zimmer Biomet.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet names Arnold Schwarzenegger as Chief Movement Officer
- Zimmer Biomet price target raised to $125 from $120 at RBC Capital
- Zimmer Biomet price target raised to $117 from $110 at Wells Fargo
- Zimmer Biomet Reports Solid Q3 2024 Performance
- Zimmer Biomet cuts FY24 adjusted EPS view to $7.95-$8.05 from $8.00-$8.15